Inhibikase Therapeutics Inc (IKT)

Dec 11, 2025

Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg - GuruFocus

Dec 11, 2025

Dec 08, 2025

Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance

Dec 08, 2025

Dec 05, 2025

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Zacks Research - MarketBeat

Dec 05, 2025

Dec 05, 2025

Is Inhibikase Therapeutics Inc. stock near bottom after decline2025 Earnings Surprises & Low Risk Entry Point Guides - Newser

Dec 05, 2025

Dec 05, 2025

Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser

Dec 05, 2025

Dec 05, 2025

Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN

Dec 05, 2025

Dec 05, 2025

How big funds are accumulating Inhibikase Therapeutics Inc. (IQT0) stockWeekly Trade Report & Risk Controlled Swing Alerts - Newser

Dec 05, 2025

Dec 04, 2025

Will Inhibikase Therapeutics Inc. (IQT0) stock benefit from mergersPortfolio Risk Summary & Real-Time Volume Trigger Notifications - Newser

Dec 04, 2025

Dec 04, 2025

Inhibikase Therapeutics, Inc. (IKT) -5.96% in After-hours: Shares Drop Amid Ongoing Offerings - Stocks Telegraph

Dec 04, 2025

Dec 04, 2025

Why Inhibikase Therapeutics Inc. (IQT0) stock trades below fair valueDollar Strength & High Yield Equity Trading Tips - Newser

Dec 04, 2025

Dec 04, 2025

Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser

Dec 04, 2025

Dec 04, 2025

Will Inhibikase Therapeutics Inc. (IQT0) stock split increase liquidityWeekly Trade Report & Weekly Breakout Watchlists - Newser

Dec 04, 2025

Dec 04, 2025

FY2025 Earnings Estimate for IKT Issued By Lifesci Capital - MarketBeat

Dec 04, 2025

Dec 04, 2025

Can Inhibikase Therapeutics Inc. stock beat market expectations this quarterTrade Entry Summary & Real-Time Buy Zone Alerts - Newser

Dec 04, 2025

Dec 04, 2025

Will Inhibikase Therapeutics Inc. stock outperform tech sector in 20252025 Market Outlook & Capital Efficient Trade Techniques - Newser

Dec 04, 2025

Dec 04, 2025

Analysts Set Expectations for IKT FY2025 Earnings - Defense World

Dec 04, 2025

Dec 03, 2025

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at Lifesci Capital - MarketBeat

Dec 03, 2025

Dec 03, 2025

Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiples2025 Market WrapUp & Fast Momentum Stock Entry Tips - Newser

Dec 03, 2025

Dec 03, 2025

Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Price Momentum & Weekly High Return Stock Forecasts - Newser

Dec 03, 2025

Dec 03, 2025

Inhibikase Therapeutics (NASDAQ:IKT) Raised to Strong-Buy at Lifesci Capital - Defense World

Dec 03, 2025

Dec 02, 2025

Inhibikase Therapeutics (IKT) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

How geopolitical tensions affect Inhibikase Therapeutics Inc. stockJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - Newser

Dec 02, 2025

Dec 01, 2025

Inhibikase Therapeutics Reports Q3 2025 Financials and Progress - MSN

Dec 01, 2025

Nov 30, 2025

Will Inhibikase Therapeutics Inc. stock recover faster than marketJuly 2025 WrapUp & Weekly Market Pulse Alerts - moha.gov.vn

Nov 30, 2025

Nov 25, 2025

Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million By Investing.com - Investing.com Australia

Nov 25, 2025

Nov 24, 2025

IKT Insider Trading - Quiver Quantitative

Nov 24, 2025

Nov 24, 2025

Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million - Investing.com

Nov 24, 2025

Nov 24, 2025

Owner Sands Capital Life Sciences Pulse Fund II LP Buys 2,068,965 ($3M) Of Inhibikase Therapeutics Inc [IKT] - TradingView

Nov 24, 2025

Nov 24, 2025

Sands Capital fund lifts IKT stake to 13.0M shares via $1.45 buy - Stock Titan

Nov 24, 2025

Nov 24, 2025

Inhibikase Therapeutics announces proposed public offering and pre-funded warrants - MSN

Nov 24, 2025

Nov 23, 2025

Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN

Nov 23, 2025

Nov 21, 2025

Inhibikase Therapeutics Inc IQT0 Stock Analysis and ForecastGrowth Stock Opportunities & Interactive Learning for Better Returns - earlytimes.in

Nov 21, 2025

Nov 21, 2025

Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury

Nov 21, 2025

Nov 21, 2025

[8-K] Inhibikase Therapeutics, Inc. Reports Material Event | IKT SEC FilingForm 8-K - Stock Titan

Nov 21, 2025

Nov 21, 2025

Inhibikase boosts cash runway with major PAH-focused equity raise - Stock Titan

Nov 21, 2025

Nov 21, 2025

Net current asset value per share of Inhibikase Therapeutics, Inc. – MUN:IQT0 - TradingView

Nov 21, 2025

Nov 21, 2025

Inhibikase Shares Climb After Revised Drug Timeline, Public Offering - marketscreener.com

Nov 21, 2025

Nov 21, 2025

Inhibikase Therapeutics Prices $100 Million Public Offering - MarketScreener

Nov 21, 2025

Nov 21, 2025

Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus

Nov 21, 2025

Nov 21, 2025

Is Inhibikase Therapeutics Inc. stock a buy before product launchesJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com

Nov 21, 2025

Nov 21, 2025

Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement - parameter.io

Nov 21, 2025

Nov 21, 2025

Inhibikase Therapeutics prices $100 million public offering - Investing.com India

Nov 21, 2025

Nov 21, 2025

Inhibikase Therapeutics (NASDAQ: IKT) prices $100M stock, warrants offering at $1.45 - Stock Titan

Nov 21, 2025

Nov 21, 2025

Inhibikase Therapeutics prices $100 million public offering By Investing.com - Investing.com Nigeria

Nov 21, 2025

Nov 20, 2025

IKT Announces Pricing Below Previous Closing Price in Latest Off - GuruFocus

Nov 20, 2025

Nov 20, 2025

Is Inhibikase Therapeutics Inc. reversing from oversold territoryTrade Signal Summary & Daily Momentum Trading Reports - newser.com

Nov 20, 2025